Relmada Therapeutics Inc (RLMD)

May 02, 2025

Relmada Therapeutics Inc expected to post a loss of 31 cents a shareEarnings Preview - TradingView

May 02, 2025

May 01, 2025

Chief Executive Officer TRAVERSA SERGIO acquire 51,407 shares of Relmada Therapeutics Inc [RLMD] - knoxdaily.com

May 01, 2025

Apr 30, 2025

It makes sense and dollars to buy Relmada Therapeutics Inc (RLMD) stock - Sete News

Apr 30, 2025

Apr 29, 2025

AbbVie’s Rinvoq is approved in giant cell arteritis; Relmada shares bladder cancer data - Endpoints News

Apr 29, 2025

Apr 29, 2025

Market Insights: Relmada Therapeutics Inc (RLMD)’s Notable Drop of -44.64, Closing at 0.36 - DWinneX

Apr 29, 2025

Apr 29, 2025

Relmada Therapeutics (RLMD) Reports Promising Phase 2 Results fo - GuruFocus

Apr 29, 2025

Apr 29, 2025

Relmada Therapeutics Presents Positive Initial Phase 2 NDV-01 Da - GuruFocus

Apr 29, 2025

Apr 28, 2025

Relmada Therapeutics Presents Positive Initial Phase 2 NDV-01 Data at AUA2025 - EIN News

Apr 28, 2025

Apr 28, 2025

Taking a Closer Look At Relmada Therapeutics Inc (RLMD) Following Its Recent Trade - knoxdaily.com

Apr 28, 2025

Apr 28, 2025

Relmada Therapeutics Reports 'Positive' Phase 2 Data for Bladder Cancer Treatment - marketscreener.com

Apr 28, 2025

Apr 28, 2025

Relmada Therapeutics, Inc. Presents Positive Initial Phase 2 NDV-01 Data at AUA2025 - marketscreener.com

Apr 28, 2025

Apr 28, 2025

Relmada reports strong Phase 2 results for bladder cancer drug By Investing.com - Investing.com Canada

Apr 28, 2025

Apr 28, 2025

Relmada reports strong Phase 2 results for bladder cancer drug - Investing.com

Apr 28, 2025

Apr 28, 2025

SEC Form 424B5 filed by Relmada Therapeutics Inc. - Quantisnow

Apr 28, 2025

Apr 28, 2025

Relmada Therapeutics (RLMD) Presents Positive Initial Phase 2 NDV-01 Data - StreetInsider

Apr 28, 2025

Apr 28, 2025

Breakthrough: Relmada's New Bladder Cancer Drug Achieves 90% Disease-Free Rate in Phase 2 Trial - Stock Titan

Apr 28, 2025

Apr 28, 2025

Relmada Therapeutics Inc: Rising -85.57% from 52-Week Low, Can the Stock Stay Afloat? - investchronicle.com

Apr 28, 2025

Apr 28, 2025

Relmada Therapeutics (RLMD) to Discuss NDV-01 Phase 2 Study Resu - GuruFocus

Apr 28, 2025

Apr 27, 2025

UPDATE -- Relmada Therapeutics To Present NDV-01 Data at AUA2025 - GuruFocus

Apr 27, 2025

Apr 27, 2025

Relmada Therapeutics Presents NDV-01 Data at AUA2025 Conference for High-Risk Non-Muscle Invasive Bladder Cancer - Nasdaq

Apr 27, 2025

Apr 27, 2025

Groundbreaking Bladder Cancer Treatment Data: Relmada's NDV-01 Takes Center Stage at AUA2025 - Stock Titan

Apr 27, 2025

Apr 25, 2025

Press Release Distribution & PR Platform - ACCESS Newswire

Apr 25, 2025

Apr 25, 2025

Stock Performance Spotlight: Relmada Therapeutics Inc (RLMD) Ends the Day at 0.74, Up by 6.86 - DWinneX

Apr 25, 2025

Apr 24, 2025

Relmada Therapeutics to Host KOL Event on Phase 2 NDV-01 Data - The Manila Times

Apr 24, 2025

Apr 24, 2025

Bridgeline Digital Secures Elite SOC 2 Type II Certification: What This Means for Enterprise Security - Stock Titan

Apr 24, 2025

Apr 24, 2025

Take off with Relmada Therapeutics Inc (RLMD): Get ready for trading - Sete News

Apr 24, 2025

Apr 23, 2025

RLMD’s price-to-free cash flow ratio: What it means for investors - uspostnews.com

Apr 23, 2025

Apr 23, 2025

Relmada Therapeutics Inc (RLMD) receives a Neutral rating from Mizuho - knoxdaily.com

Apr 23, 2025

Apr 22, 2025

RLMD Stock: A Comprehensive Analysis and Forecast - investchronicle.com

Apr 22, 2025

Apr 18, 2025

Relmada Therapeutics (NASDAQ:RLMD) Trading Down 0.8% – Should You Sell? - Defense World

Apr 18, 2025

Apr 14, 2025

Relmada Therapeutics To Present NDV-01 Data at AUA2025 | RLMD St - GuruFocus

Apr 14, 2025

Apr 14, 2025

UPDATE — Relmada Therapeutics To Present NDV-01 Data at AUA2025 - TradingView

Apr 14, 2025

Apr 14, 2025

Revolutionary Cancer Therapy NDV-01 Data: Game-Changing Results Coming to AUA2025 - Stock Titan

Apr 14, 2025

Apr 14, 2025

Relmada Therapeutics To Present NDV-01 Data at AUA2025 - Yahoo Finance

Apr 14, 2025

Mar 30, 2025

Relmada outlines plans for NDV-01 Phase 2 results presentation and sepranolone development - MSN

Mar 30, 2025

Mar 29, 2025

Relmada Therapeutics, Inc. (NASDAQ:RLMD) Q4 2024 Earnings Call Transcript - Insider Monkey

Mar 29, 2025

Mar 28, 2025

Relmada Therapeutics: Strategic Acquisitions and Pipeline Progress - TipRanks

Mar 28, 2025

Mar 28, 2025

Relmada Therapeutics pivots from psilocybin to cancer, neurological disorders - Crain's Chicago Business

Mar 28, 2025

Mar 28, 2025

Relmada Therapeutics Inc (RLMD) Q4 2024 Earnings Call Highlights: Strategic Acquisitions and ... - Yahoo

Mar 28, 2025

Mar 28, 2025

Relmada Therapeutics Inc (RLMD) Q4 2024 Earnings Call Highlights - GuruFocus

Mar 28, 2025

Mar 27, 2025

Relmada Therapeutics Reports 2024 Financial Results and Strategic Progress - TipRanks

Mar 27, 2025

Mar 27, 2025

Earnings call transcript: Relmada Therapeutics Q4 2024 sees improved EPS By Investing.com - Investing.com South Africa

Mar 27, 2025

Mar 27, 2025

Earnings call transcript: Relmada Therapeutics Q4 2024 sees improved EPS - Investing.com India

Mar 27, 2025

Mar 27, 2025

RELMADA THERAPEUTICS Earnings Results: $RLMD Reports Quarterly Earnings - Nasdaq

Mar 27, 2025

Mar 27, 2025

Relmada Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView

Mar 27, 2025

Mar 27, 2025

Relmada Therapeutics Reports Fourth Quarter and Full Year 2024 Results and Provides Business Update - The Manila Times

Mar 27, 2025

Mar 27, 2025

Relmada Cuts Losses by 25%: Key Pipeline Programs Hit Critical Phase in 2025 - Stock Titan

Mar 27, 2025

Mar 26, 2025

Relmada Therapeutics Inc -On March 24, Enters Exclusive License Agreement With Trigone PharmaSEC Filing - MarketScreener

Mar 26, 2025

Mar 26, 2025

Insights Ahead: Relmada Therapeutics's Quarterly EarningsRelmada Therapeutics (NASDAQ:RLMD) - Benzinga

Mar 26, 2025

Mar 26, 2025

Mizuho maintains Relmada stock neutral with $1.00 target By Investing.com - Investing.com Canada

Mar 26, 2025

Mar 26, 2025

Relmada Therapeutics to Report Fourth Quarter 2024 Financial Results on Thursday, March 27, 2025 - Quantisnow

Mar 26, 2025